Recent news on Peginterferon Alfa-2A

Cure for Hepatitis C Announced  -  25 May 2007
EndoNurse,...viral response (SVR) following treatment with either Pegasys (peginterferon alfa-2a) monotherapy or combination therapy with Pegasys and ribavirin.

Cure for hepatitis C announced  -  May 22, 2007
HULIQ,...viral response (SVR) following treatment with either Pegasys (peginterferon alfa-2a) monotherapy or combination therapy with Pegasys and ribavirin.

Data Suggest that PEGASYS® May be an Option in Hepatitis C ...  -  May 21, 2007
WebWire (press release),...due to adverse events within the first 12 weeks, were able to complete 12 weeks of treatment with PEGASYS® (peginterferon alfa-2a) and ribavirin.

Cure for Hep C?  -  May 21, 2007
Ivanhoe,...(HCV) re-emerged in 997 patients who were successfully treated with either Pegasys (peginterferon alfa-2a) alone or when it is taken with ribavirin.

PEGASYS® Study Authors Conclude that Patients Successfully Treated ...  -  May 22, 2007
WebWire (press release),PEGASYS® (peginterferon alfa-2a) had no detectable virus up to seven years later – validating the use of the word “cured� to describe these patients,

Roche updates on flu manufacturing; expands US unit  -  Apr 26, 2007
OutSourcing-Pharma.com,...including cancer drug Xeloda (capecitabine), Pegasys (peginterferon alfa-2a) for hepatitis, Tamiflu and Xenical (orlistat) for obesity.

Roche updates on flu manufacturing; expands US unit  -  26 Apr 2007
In-PharmaTechnologist.com,...including cancer drug Xeloda (capecitabine), Pegasys (peginterferon alfa-2a) for hepatitis, Tamiflu and Xenical (orlistat) for obesity.

Hepatitis C Patients With Advanced Kidney Disease Benefit From ...  -  Apr 16, 2007
DG NewsResults at 12 weeks showed that in patients receiving peginterferon alfa-2a 135 mcg/week, there were significantly more virological responders at week 12

Telaprevir Plus Peginterferon Alfa-2a and Ribavirin Drives 79% of ...  -  Apr 16, 2007
DG News...[Presentation Title: Results of an Interim Analysis of a Phase 2 Study of Telaprevir (VX-950) With Peginterferon alfa-2a and Ribavirin in Previously

Treatment Optimisation With PEGASYS Plus COPEGUS Offers Patients ...  -  Apr 12, 2007
Juraforum.de,Patients with genotype1 hepatitis C (HCV) who clear the virus within a month of startingtreatment with PEGASYS (peginterferon alfa-2a (40KD)) plus

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Apr 6, 2007
Drug Newswire (press release),Over 1000 patients will be enrolled into PROGRESS and these patients will be randomized to receive one of four dosing regimens of peginterferon alfa-2a

Sustained Response to Anti-Hepatitis C Virus Drugs Results in Cure ...  -  Apr 16, 2007
DG NewsOf patients who achieved a SVR, 163 patients who had HCV monoinfection were treated with peginterferon alfa-2a alone; 741 patients with HCV monoinfection

Treatment Optimisation With PEGASYS Plus COPEGUS Offers Patients ...  -  Apr 12, 2007
campus med,Patients with genotype 1 hepatitis C (HCV) who clear the virus within a month of starting treatment with PEGASYS (peginterferon alfa-2a (40KD)) plus COPEGUS

Human Genome Sciences reports results of phase 2b trial of Albuferon  -  Apr 17, 2007
News-Medical.net,..."The interim data presented at EASL suggest that Albuferon may offer efficacy at least comparable to peginterferon alfa-2a, with half the injections and the

Analysis: Total hepatitis C cure possible  -  Apr 12, 2007
Science Daily (press release)Of the patients who did achieve a sustained virologic response, 163 patients who only had hepatitis C infections were treated with peginterferon alfa-2a

Higher Doses of Ribavirin Are Effective in Hepatitis C Virus ...  -  Apr 13, 2007
DG News...[Presentation title: Management of Chronic Hepatitis C in a Diverse Population With Peginterferon Alfa-2A and Ribavirin: Final Results of the Canadian

Human Genome Sciences Reports Positive Interim Results of Phase 2b ...  -  Apr 14, 2007
PR-Inside.com (Pressemitteilung),Albuferon may offer efficacy at least comparable to peginterferon alfa-2a, with half the injections and the potential for less impairment of quality of life

Vertex Pharmaceuticals Announces New Data for Investigational HCV ...  -  Apr 11, 2007
PharmaLive.com (press release),A late-breaker presentation titled, "Results of an Interim Analysis of a Phase 2 Study of Telaprevir (VX-950) with Peginterferon alfa-2a and Ribavirin in

Additional Preclinical Data Presented on Valopicitabine Combined ...  -  Apr 12, 2007
PR Newswire (press release),Inc. 1 Fried, M. et al., Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection. New England Journal of Medicine 2002.

EASL: Sustained Virologic Response Equals Cure for HCV Infection  -  Apr 12, 2007
MedPage Today,Of the patients who achieved a sustained virologic response, 163 who only had HCV infections were treated with peginterferon alfa-2a monotherapy;

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Apr 6, 2007
Drug Newswire (press release),Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82. 2. Hadziyannis SJ, Sette H, Jr., Morgan TR,

Vertex to meet hepatitis C patients' needs?  -  Apr 17, 2007
LabTechnologist.com,...with Roche's pegylated interferon Pegasys (peginterferon alfa-2a; peg-IFN) and ribavirin (RBV) enabled some patients to clear the virus in 12 weeks.

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Mar 14, 2007
news aktuell (Pressemitteilung),The four dosing regimens are: Arm 1 - A fixed-dose induction (360 mg) of peginterferon alfa-2a (40KD) given once every week for the first 12 weeks,

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Mar 14, 2007
PR Newswire UK (press release),Over 1000 patients will be enrolled into PROGRESS and these patients will be randomized to receive one of four dosing regimens of peginterferon alfa-2a

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Mar 14, 2007
Earthtimes.orgArm 1 - A fixed-dose induction (360 mg) of peginterferon alfa-2a (40KD) given once every week for the first 12 weeks, then the standard licensed 180 microg

Roche starts PROGRESS trial in Poland  -  Mar 21, 2007
Polish Market,The international study will evaluate the effect of Pegasys (peginterferon alfa-2a (40KD)) and Copegus (ribavirin) in hepatitis C patients who have a high

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Mar 5, 2007
PR Newswire UK (press release),Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82. 2. Hadziyannis SJ, Sette H, Jr., Morgan TR,

Human Genome Sciences Announces Positive Interim Results of Phase ...  -  Feb 28, 2007
PharmaLive.com (press release),The fourth treatment group serves as the active control group and received 180-mcg doses of subcutaneously administered peginterferon alfa-2a (Pegasys) once

Roche Driving PROGRESS in Treatment of Hepatitis C  -  Mar 14, 2007
WebWire (press release),This study will evaluate the effect of PEGASYS® (peginterferon alfa-2a) and ribavirin in patients who have a high level of genotype 1 virus in their blood

Human Genome Sciences Initiates Phase 3 Clinical Trial of ...  -  Feb 28, 2007
PharmaLive.com (press release),...on health-related quality of life of Albuferon in combination with ribavirin, versus PEGASYS (peginterferon alfa-2a) in combination with ribavirin.

Hepatitis C Treatment Center  -  Feb 6, 2007
WebMDPEGASYS (Peginterferon alfa-2a), like other alpha interferons, can cause fatal or make life-threatening problems worse (like mental, immune system, heart,

Cancer Research chief questions firms' clinical study set-up  -  Jan 31, 2007
Pharma Times (subscription),...period of use reduced, pointing to an on-going study into halving the period of use for its hepatitis C drug Pegasys (peginterferon alfa-2a).

Taking TRIPS to India — Novartis, Patent Law, and Access to Medicines  -  Feb 7, 2007
New England Journal of Medicine (subscription),...government has granted only one patent on a pharmaceutical product — to Hoffmann–La Roche, for its hepatitis C therapy, peginterferon alfa-2a (Pegasys).

Copegus Approved In Japan As Combination Therapy With Pegasys For ...  -  Jan 29, 2007
Medical News Today (press release),Roche and Chugai announced today that the combination of Copegus (ribavirin) plus Pegasys (peginterferon alfa-2a (40KD)) has been approved in Japan

Roche Posts Outstanding Results for 2006  -  Feb 7, 2007
PharmaLive.com (press release),Despite an overall decline in market volume in the US and competition from a combination treatment in Japan, sales of Pegasys (peginterferon alfa-2a),

HGS initiates first trial in hepatitis C program  -  Dec 19, 2006
Pharmaceutical Business Review...and impact on health-related quality of life of Albuferon in combination with ribavirin, versus peginterferon alfa-2a in combination with ribavirin.

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med.

HGS initiates first trial in hepatitis C program  -  Dec 19, 2006
Pharmaceutical Business Review...and impact on health-related quality of life of Albuferon in combination with ribavirin, versus peginterferon alfa-2a in combination with ribavirin.

Valeant Pharmaceuticals Reports VISER2 Results for Viramidine ...  Sep 12, 2006
...evaluated a fixed 600 mg BID dose of Viramidine to a weight-based 1,000/1,200 mg daily dose of ribavirin, both in combination with peginterferon alfa 2a. ... -PharmaLive.com

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med.

Racial differences in hepatitis C viral responses  Aug 16, 2006
African American patients with hepatitis C (HCV) infections experience a lower response rate to the peginterferon alfa-2a and ribavirin combination treatment ... -News-Medical.net

African Americans Have Lower Response Rate To Standard Therapy For  Aug 16, 2006
August 15, 2006) – African American patients with hepatitis C (HCV) infections experience a lower response rate to the peginterferon alfa-2a and ribavirin ... -WebWire

African-Americans Have A Reduced Response To Hepatitis C Treatment  Aug 17, 2006
...the African American patients with hepatitis C (HCV) infections experience a reduced response in the rate in treatment with peginterferon alfa-2a and ribavirin ... -MedIndia

Relapse to Opioid Use After Treatment of Chronic Hepatitis C With ...  Jul 28, 2006
Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K, Gries JM, Yalamanchili S: Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in ... -Am J Psychiatry (subscription)



Antibodies Neutralizing Peginterferon Alfa during Retreatment of ...  Mar 22, 2006
2 , 3 , 4 We describe a patient who did not have a virologic response to peginterferon and had a virtual absence of circulating peginterferon alfa-2a but had ... - New England Journal of Medicine (subscription)

- Interim 12-Week Data Suggest At Least Comparable Antiviral ...  Mar 14, 2006
The fourth treatment group serves as the active control group and receives 180-mcg doses of subcutaneously administered peginterferon alfa-2a (Pegasys) at 7 ... - PR Newswire

Idenix Announces Thirteen Data Presentations at the 2006 European ...  Mar 17, 2006
Dr. Zhou will present "Absence of Pharmacokinetic Drug-Drug Interaction Between Telbivudine and Peginterferon alfa-2a or Cyclosporine in Healthy Subjects" in ... - PR Newswire



People With Chronic Hepatitis B To Benefit From Guidance On New ...  Feb 21, 2006
...- - - - Peginterferon alfa-2a is recommended as an option for ... treatment with interferon alfa or peginterferon alfa-2a is poorly tolerated or contraindicated. ... - Medical News Today,

CROI: rapid response predicts success in HIV/HCV coinfected ...  Feb 17, 2006
...infected patients with HCV genotype 1(G1) infection who have a rapid virological response (RVR) at week 4 of treatment with peginterferon alfa-2a (40KD) (PEG ... - Aidsmap,

First-Time Generic Approvals: Copegus, Tegretol, Roxicodone  Jan 24, 2006
Ribavirin tablets are indicated for use with peginterferon alfa-2a in the treatment of adults with chronic hepatitis C virus (HCV) infection who have ... - Medscape (subscription)

Human Genome Sciences Reports on Progress Toward Commercialization ...  Jan 10, 2006
The fourth treatment group serves as the active control group and receives weekly 180-mcg doses of subcutaneously administered Pegasys (peginterferon alfa-2a). ... - MSN Money

Increase ribavirin dose for better HCV treatment response in ...  Jan 18, 2006
Fried MW et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347(13): 975-982, 2002. - Aidsmap

Zacks.com Announces That Vivian Lewis Highlights the Following ...  Jan 17, 2006
Shipment began of the AB-rated generic equivalent of Roche's Copegus (R), used in combination with peginterferon alfa-2a to treat adults with chronic hepatitis ... - Business Wire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional